Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 50Lymphoma, Non-Hodgkin 36Lymphoma, Large B-Cell, Diffuse 29Lymphoma 29Lymphoma, Mantle-Cell 26Lymphoma, B-Cell, Marginal Zone 22Lymphoma, B-Cell 18Recurrence 12Neoplasms 9Leukemia, B-Cell 6Burkitt Lymphoma 5Waldenstrom Macroglobulinemia 3Neoplasm, Residual 3Leukemia 3Leukemia, Hairy Cell 2Disease 2Tumor Lysis Syndrome 1Part1: Advanced B-cell Malignancies 1Mycosis Fungoides 1Mature B-cell Malignancies 1Mature B-Cell Malignancies 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphatic Diseases 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphoid 1

Interventions

duvelisib 3parsaclisib 1obinutuzumab 1liposomal doxorubicin 1chiauranib 1Taxes 1Rituximab 1Panobinostat 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Everolimus 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × obinutuzumab × Lymphoid × Clear all
NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

SecuraBio

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡